

Zucara is developing ZT-01, the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in diabetes patients. Current therapies are reactive, “rescuing” patients from potentially dangerous low blood sugar levels. ZT-01 offers significant benefit to diabetes patients by preventing hypoglycemia.

**50%** of hypoglycemia events happen overnight, when patients feel most vulnerable

up to **27%** of unexplained deaths in T1D involves night-time hypoglycemia<sup>3</sup>

*"Hypoglycemia is clearly an under-recognized risk factor for death and cardiovascular disease in people with diabetes"*<sup>1</sup>

Each year in the US alone, hypoglycemia is responsible for approximately<sup>2</sup>


**1.4M** emergency hospital visits/ hospitalizations

**3,000** deaths


1. Diabetes World Awake study. Conducted by Aequus Research Ltd. July – September 2013. Funded by Novo Nordisk. 1,1107 patients with either T1D or T2D; "Dead in bed": a tragic complication of type 1 diabetes mellitus, Pubmed 2010. O'reilly and al. 2. Senior author Elizabeth Selvin, Ph.D., a professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health in Baltimore, March, 2017 3. Singh ADA 2013. Singh, EASD 2012. Geiss CDC CDC2012 Statistics. Kaufman, ADA abstract 2015.

### Night-time Administration to Prevent Overnight Hypoglycemia

ZT-01 (an octapeptide analog) works by blocking the activity of somatostatin, a pancreatic hormone that is not properly regulated in insulin-dependent diabetes. Blocking somatostatin restores glucagon secretion, which restores blood glucose levels.



● ZT-01, Somatostatin Receptor Type 2 (SSRT2) Antagonist



## ZT-01 Efficacy Results Highlights


8 studies conducted across 3 models with ZT-01 efficacy replicated in 2 independent labs

Improved glucagon counterregulation with treatment



Resistance to insulin-induced hypoglycemia

Attractive profile for rapidly generating human PoC, with financing secured to the clinic



### Leadership

Michael Midmer  
Chief Executive Officer

Michael Riddell  
Chair, Scientific Advisory Board

Richard Liggins  
Chief Scientific Officer

Luc Mainville  
Chair of Board  
CFO, Valeo Pharma

Claude Piche  
Independent Director  
CEO, Locemia Solutions

### Contact

Michael Midmer, CEO  
Zucara Therapeutics Inc.  
mmidmer@zucara.ca  
MaRS Centre, Suite 1300  
661 University Avenue  
Toronto, ON M5G 0B7